SCHEMBL296925

SCHEMBL296925

COc1cc(CN(C)C(=O)C(C)(CCN2CCC(NS(C)(=O)=O)CC2)c2ccc(Cl)c(Cl)c2)ccc1OC(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 5/20 0.52
TACR2 P21452 3/20 0.52
TACR1 P25103 3/20 0.52
UTS2R Q9UKP6 1/20 0.39
ALDH1A1 P00352 2/20 0.36
SIGMAR1 Q99720 2/20 0.36
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
RORC P51449 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
RAB9A P51151 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
UBE2N P61088 1/20 0.35
HTT P42858 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
CRHBP P24387 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296619 0.90 TACR3 (0.58) TACR3TACR2TACR1UTS2RSIGMAR1
SCHEMBL3858239 0.88 TACR3 (0.50) TACR3TACR2TACR1ALDH1A1RORC
SCHEMBL296958 0.88 TACR3 (0.60) TACR3TACR2TACR1ALDH1A1SIGMAR1
SCHEMBL3640738 0.85 TACR3 (0.48) TACR3TACR2TACR1ALDH1A1SMN1; SMN2
SCHEMBL3856444 0.85 TACR3 (0.47) TACR3TACR2TACR1UTS2RALDH1A1
SCHEMBL3865337 0.85 TACR3 (0.47) TACR3TACR2TACR1UTS2RALDH1A1
SCHEMBL3856438 0.85 TACR3 (0.47) TACR3TACR2TACR1UTS2RALDH1A1
SCHEMBL297970 0.85 TACR3 (0.61) TACR3TACR2TACR1SIGMAR1
SCHEMBL297667 0.85 TACR3 (0.59) TACR3TACR2TACR1SIGMAR1
SCHEMBL296934 0.84 TACR3 (0.52) TACR3TACR2TACR1SIGMAR1CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200982-B1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-03-14 EP disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
WO-2009033995-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-03-19 WO disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 TACR3 95/4885TACR2 21/4885TACR1 26/4885
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds EIF2AK2, HAVCR2, MAVS TACR3 3080/4885TACR2 1134/4885TACR1 619/4885
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 TACR3 95/4885TACR2 21/4885TACR1 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.